Current Advances in Japanese Encephalitis Virus Drug Development by Jiao Guo, Yunqi Mi, Yan Guo, Yang Bai, Meihua Wang, Wei Wang, Yang Wang

Subjects: Get full text

The assessment on cross immunity with smallpox virus and antiviral drug sensitivity of the isolated mpox virus strain WIBP-MPXV-001 in China by Yan Zeng, Xiaoke Liu, Yuwei Li, Jia Lu, Qin Wu, Demiao Dan, Shiyun Lv, Fei Xia, Chunxia Hu, Jiali Li, Hao Zhang, Hongqiao Du, Rui Jia, Kai Duan, Zejun Wang, Xinguo Li, Xiaoming Yang

Get full text

Retraction for Li et al., “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs” by Yanbai Li, Shanshan Huo, Zhe Yin, Zuguang Tian, Fang Huang, Peng Liu, Yue Liu, Fei Yu

Get full text

Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs by Allan Peres-da-Silva, Adilson José de Almeida, Elisabeth Lampe

Get full text

Editorial: Antiviral drug discovery against pathogens of pandemic concern: Advancements in target site identification and structure-based drug development by Krishna M. Padmanabha Das, Krishna M. Padmanabha Das

Get full text

Spherical PEG/SiO2 promising agents for Lamivudine antiviral drug delivery, a molecular dynamics simulation study by Sahar Razzaghi, Mohsen Vafaee, Bahar Kharazian, Mokhtar Nasrollahpour

“…Spherical polyethylene glycol (PEG) and spherical silica (SiO2) are novel attractive nanocarriers as drug delivery agents, especially they are recently noticed to be reliable for antiviral drugs like anti-HIV, anti-covid-19, etc. Lamivudine (3TC) is used as a first line drug for antiviral therapy and the atomic view of 3TC-PEG/SiO2 complexes enable scientist to help improve treatment of patients with viral diseases. …”
Get full text

P1096: TREATMENT OF HEPATITIS C-ASSOCIATED MARGINAL ZONE LYMPHOMA(HCV+LMZ) WITH DIRECT-ACTING ANTIVIRAL DRUGS (DAAS) by Sergey Lepkov, Gayne Tumyan, Oleg Kolomeytsev, Svetlana Lunina, Anastasia Semenova, Natalia Kuprihina, Daria Tupicina, Natalia Kokosadze, Svetlana Borisovckay, Natalia Gavrilina, Kira Savkina, Roman Ivashenko, Olga Manuilova, Oleg Zaharov, Natalia Chernova, Maria Blagova, Efim Pozharskiy, Julia Ribukina, Vladimir Lazarev, Olga Ettinger, Igor Nikitin

Get full text

Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic by Giulia Garzi, Francesco Cinetto, Francesco Cinetto, Davide Firinu, Giulia Di Napoli, Gianluca Lagnese, Alessandra Punziano, Patrick Bez, Patrick Bez, Bianca Laura Cinicola, Giulia Costanzo, Riccardo Scarpa, Riccardo Scarpa, Federica Pulvirenti, Marcello Rattazzi, Marcello Rattazzi, Giuseppe Spadaro, Isabella Quinti, Cinzia Milito

Subjects: Get full text

Solubility Data, Solubility Parameters and Thermodynamic Behavior of an Antiviral Drug Emtricitabine in Different Pure Solvents: Molecular Understanding of Solubility and Dissolution by Faiyaz Shakeel, Nazrul Haq, Ibrahim Alsarra, Sultan Alshehri

Get full text

Evaluation of the efficacy and safety of a complex antiviral drug based on antibodies in the treatment of adult patients with acute respiratory viral infection by Rustem F. Khamitov, Vladimir V. Nikiforov, Andrey A. Zaytsev, Irina N. Tragira

Get full text

Targeting the receptor binding domain and heparan sulfate binding for antiviral drug development against SARS-CoV-2 variants by Zi-Sin Yang, Tzong-Shiun Li, Yu-Sung Huang, Cheng-Chung Chang, Ching-Ming Chien

“…Therefore, it might be a reasonable strategy for antiviral drug design to interfere with the RBD in the HS binding site. …”
Get full text

In vitro activity of six antiviral drugs against equid alphaherpesvirus type 1 indicates ganciclovir as promising drug for in vivo studies by Amanda Lovato de Oliveira, Juliana Felipetto Cargnelutti, Ana Paula Gnocato Mortari, Eduardo Furtado Flores, Rudi Weiblen

Get full text

Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs by Lena Parigger, Lena Parigger, Andreas Krassnigg, Tobias Schopper, Amit Singh, Amit Singh, Katharina Tappler, Katharina Köchl, Michael Hetmann, Michael Hetmann, Michael Hetmann, Karl Gruber, Karl Gruber, Karl Gruber, Karl Gruber, Georg Steinkellner, Georg Steinkellner, Georg Steinkellner, Christian C. Gruber, Christian C. Gruber, Christian C. Gruber, Christian C. Gruber

“…We report a remarkable increase in mutational variability in an eight-residue long consecutive region (R188-G195) near the active site since December 2021.DiscussionThe increased mutational variability in close proximity to an antiviral-drug binding site as described herein may suggest the onset of the development of antiviral resistance. …”
Get full text

Off-Label Drug Use Medication Guidelines of Immunotherapy Drugs and COVID-19 Antiviral Drugs for COVID-19 in Vulnerable Populations by Li Ye, Liu Xingling, Pan Yunqi, Lin Yanduan, Xu Lejia, Zheng Danwei, Jiang Caiyun, Yang Qi, Mai Haiyan

Subjects: “…|immunotherapy drug|covid-19 antiviral drug|covid-19|off-label drug use|vulnerable population…”
Get full text

A sustainable approach for the degradation kinetics study and stability assay of the SARS-CoV-2 oral antiviral drug Molnupiravir by Fadwa H. Edrees, Mohammed E. Draz, Ahmed S. Saad, Sherif F. Hammad, Heba M. Mohamed

“…Abstract Molnupiravir (MPV) is the first direct-acting oral antiviral drug that effectively decreases nasopharyngeal infections with SARS-CoV-2 virus. …”
Get full text

The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation by О. M. Tsiroulnikova, D. V. Umrik, I. A. Miloserdov, Е. Т. Egorova, R. A. Latypov

Get full text

Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: a modeling study by Iwanami, S, Ejima, K, Kim, KS, Noshita, K, Fujita, Y, Miyazaki, T, Kohno, S, Miyazaki, Y, Morimoto, S, Nakaoka, S, Koizumi, Y, Asai, Y, Aihara, K, Watashi, K, Thompson, RN, Shibuya, K, Fujiu, K, Perelson, AS, Iwami, S, Wakita, T

“…<p><strong>Background</strong><br> Development of an effective antiviral drug for Coronavirus Disease 2019 (COVID-19) is a global health priority. …”

Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy by Sania Batool, Santosh Chokkakula, Min-Suk Song

Subjects: Get full text

Construction of Fosmid-based SARS-CoV-2 replicons for antiviral drug screening and replication analyses in biosafety level 2 facilities by Shunta Takazawa, Tomohiro Kotaki, Satsuki Nakamura, Chie Utsubo, Masanori Kameoka

Subjects: Get full text

Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials by Palak K. Parikh, Nisha H. Parikh, Mahalakshmi B, Ketan M. Ranch, Sai H.S. Boddu, Jayachandra Babu R, Amit K. Tiwari

“…An up-to-date comprehensive analysis is required to examine the current state of antiviral drug discovery and understand the new trends in antiviral approaches. …”
Get full text